Rationale for Correct Answer

The correct answer is: Siponimod

The disease-modifying therapy (DMT) siponimod was associated with improved cognitive processing speed (CPS) in a randomized, placebo-controlled clinical trial.1 Other DMTs are also associated with improved cognition, including alemtuzumab, glatiramer acetate, interferon β-1a and β-1b, natalizumab, and ocrelizumab.2-4 The Alzheimer drugs memantine and donepezil lack efficacy in patients with MS.5,6 Compensatory strategies can be effective in improving memory and recall in patients with MS, not CPS. Restorative training is another technique associated with a variety of cognitive improvements, including attention, CPS, executive function, and memory.7

References:
1. Cree BA et al. Eur Neurol. 2002;47:11-14.
2. Riepl E et al. Front Neurol. 2018;8:730.
3. Miller E et al. Curr Neuropharmacol. 2018;16:475-483.
4. Benedict R et al. Neurology. 2022;98(18 Supplement):647. Abstract P1-1 Virtual.
5. Turalde CWR et al. Front Neurol. 2021;11:574748.
6. Krupp LB et al. Neurology. 2011;76:1500-1507.
7. Benedict R et al. Lancet Neurol. 2020;19:860-871.